Request for Proposals: Leukemia & Lymphoma Society Transforming CURES Initiative (TCI) - Intercepting Progression to Advanced Myeloid Blood Cancers

Request for Proposals: Leukemia & Lymphoma Society Transforming CURES Initiative (TCI) - Intercepting Progression to Advanced Myeloid Blood Cancers The Leukemia & Lymphoma Society (LLS) is proud to announce the "Transforming CURES Initiative (TCI) - Intercepting Progression to Advanced Myeloid Blood Cancers," a new Request for Proposals (RFP) to identify and develop novel, safe and effective treatment paradigms for patients with hematological malignancies. The near term goal of this program is to advance the scientific and medical understanding of myeloid disease progression from an early stage to frank malignancy. LLS is very pleased that Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, will be sponsoring this initiative, in part, along with LLS. Description of the Awards: The overall goal is to understand the molecular hematopoietic events that mediate progression of myeloid malignancies from chronic pre-leukemic, or early stage myeloid disorders, such as myelodysplastic syndromes or myeloproliferative neoplasms, to frank hematologic malignancy that could lead to novel therapeutics to control such disease progression. Proposal topics of interest might include, but are not limited to: Identify the molecular, cellular and epigenetic drivers of progression to leukemia Identify the role of the immune system in progression from molecular alteration to full blown leukemia Understand the role of the microen...
Source: ScanGrants feed - Category: Research Authors: Source Type: funding